BioPharma
Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers
The Chinese pharmaceutical firms are increasingly looking out for the local reagent suppliers so as to cut the costs as well as delivery times....
Press Releases
Record international attendance at CPHI & PMEC China 2025 as China in-licensing deals and international partnering increase
China’s biotech sector is now a key driver of innovation across global pipelines, as CPHI Shenzhen prepares for largest ever influx of foreign dealmakers
Sino-international...
Packaging & Labelling
Autopack to host biggest packaging machinery stand at PPMA Total 2025
Leading independent integrator of packaging lines Autopack will showcase a range of cutting-edge automated equipment at PPMA Total 2025, which takes place at Birmingham’s NEC from...
Interviews
Conversation with Billy Amzal, Phastar’s new Head of Strategic Consulting
You’ve had a diverse career across biotech, pharma, consulting, and public health. What experiences have shaped your approach to data science and strategic consulting?
I...
Drug Research
Quantum Computing Advances Make Way for Lifesaving Therapies
The fact is that there is something very profoundly poetic about the convergence of quantum physics along with pharmaceutical endeavors. In the sophisticated melody...
Press Releases
Friends of Cancer Research and MMS Collaborate to Develop Decision Frameworks for Interim Overall Survival Data in Oncology Trials
MMS, a global, data-focused clinical research organization (CRO), announced today that it has been chosen by Friends of Cancer Research (Friends), a leading nonprofit...
Clinical Trials
PADCEVâ„¢ Plus KEYTRUDAâ„¢ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read















